Contemporary Practices in Core Safety Pharmacology Assessments

Baird, Theodore J.; Gauvin, David V.; Dalton, Jill A.

doi:10.1016/b978-0-12-387815-1.00006-x

Cited by 1 publication

(1 citation statement)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite being more laborious, the manual hERG assay is an indicator of function, as opposed to binding technique, which only measures the affinity of the test article to the receptor. Additionally, this method more easily fits the requirements of GLP at this stage of development (71). …”

Section: Safety Studiesmentioning

confidence: 99%

Non-clinical studies in the process of new drug development - Part II: Good laboratory practice, metabolism, pharmacokinetics, safety and dose translation to clinical studies

Andrade¹,

Bento²,

Cavalli³

et al. 2016

Braz J Med Biol Res

135

View full text Add to dashboard Cite

The process of drug development involves non-clinical and clinical studies. Non-clinical studies are conducted using different protocols including animal studies, which mostly follow the Good Laboratory Practice (GLP) regulations. During the early pre-clinical development process, also known as Go/No-Go decision, a drug candidate needs to pass through several steps, such as determination of drug availability (studies on pharmacokinetics), absorption, distribution, metabolism and elimination (ADME) and preliminary studies that aim to investigate the candidate safety including genotoxicity, mutagenicity, safety pharmacology and general toxicology. These preliminary studies generally do not need to comply with GLP regulations. These studies aim at investigating the drug safety to obtain the first information about its tolerability in different systems that are relevant for further decisions. There are, however, other studies that should be performed according to GLP standards and are mandatory for the safe exposure to humans, such as repeated dose toxicity, genotoxicity and safety pharmacology. These studies must be conducted before the Investigational New Drug (IND) application. The package of non-clinical studies should cover all information needed for the safe transposition of drugs from animals to humans, generally based on the non-observed adverse effect level (NOAEL) obtained from general toxicity studies. After IND approval, other GLP experiments for the evaluation of chronic toxicity, reproductive and developmental toxicity, carcinogenicity and genotoxicity, are carried out during the clinical phase of development. However, the necessity of performing such studies depends on the new drug clinical application purpose.

show abstract

Section: Safety Studiesmentioning

confidence: 99%